stockrowBio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
Follow TECH
Alert me
Bio-Techne Corp (TECH) Net margin
Bio-Techne Corp's net margin over the twelve months to 30 June 2026 was 15.0%. Over the past ten years it has ranged from 6.02% (fiscal 2025) to 31.0% (fiscal 2020); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | 15.0% | 8.95 |
| FY2025 | 6.02% | (8.48) |
| FY2024 | 14.5% | (10.60) |
| FY2023 | 25.1% | 0.49 |
| FY2022 | 24.6% | 9.53 |
| FY2021 | 15.1% | (15.96) |
| FY2020 | 31.0% | 17.58 |
| FY2019 | 13.5% | (6.16) |
| FY2018 | 19.6% | 6.11 |
| FY2017 | 13.5% | (7.43) |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jun 2026 | 17.0% | 0.62 |
| Mar 2026 | 16.4% | 3.54 |
| Dec 2025 | 12.9% | (0.48) |
| Sep 2025 | 13.3% | 18.91 |
| 42 more quarters | Free account |
Against its own ten years
Net margin against peers
| Company | Net margin |
|---|---|
| TGTX TG Therapeutics, Inc. compare | 55.2% |
| TECH Bio-Techne Corp | 15.0% |
| CAI Caris Life Sciences,�Inc. compare | 9.16% |
| PCVX Vaxcyte, Inc. compare | 0.00% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| KYMR Kymera Therapeutics, Inc. compare | 0.00% |
| BMRN BioMarin Pharmaceutical Inc. compare | −0.52% |
| TWST Twist Bioscience Corporation compare | −31.7% |
| IBRX ImmunityBio, Inc. compare | −598.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on TECH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement